IGF2 and osteosarcoma: The expression of insulin-like growth factor 2 (IGF2) has been shown to induce a state of dormancy in osteosarcoma, leading to acquired resistance against chemotherapeutic drugs and the subsequent, future endangerment of minimal residual disease.